Resolution Therapeutics CEO Amir Hefni spoke with Stephen Adams of Optimum Strategic Communications on everything from the scientific origins of Resolution to our upcoming data presentations at EASL 2024 on the latest episode of Optimum TV.
Resolution CEO, Dr Amir Hefni, talks about upcoming EASL presentations on Optimum TV
More Stories
06/10/2026
Resolution Therapeutics to present interim EMERALD data on RTX001 as a late-breaker at AASLD 2026
Interim data from Phase I/II EMERALD study for RTX001, Resolution’s engineered Regenerative Macrophage Therapy, accepted as late-breaking presentation. Dr. Lara Campana to present preclinical data on intravenous Regenerative Macrophage Therapy for decompensated cirrhosis.
11/09/2026
Resolution Therapeutics completes enrollment in Phase I/II EMERALD clinical trial evaluating RTX001 in end-stage liver disease
15 patients dosed with RTX001, an engineered Regenerative Macrophage Therapy designed to address inflammation and fibrosis. EMERALD is evaluating safety and efficacy of RTX001 in patients with end-stage liver disease and a history of decompensated liver cirrhosis. Interim clinical data expected in Q4 2026
01/09/2026
Resolution Therapeutics partners with the Blood Centers of America, Inc. to support broad patient access to its experimental Regenerative Macrophage Therapy in the U.S.
Partnership will support Resolution’s pivotal clinical program in 2027, as well as future commercial preparedness for RTX001, its lead asset in patients with end-stage liver disease (ESLD) Primary goal is to ensure patients can access treatment in the community setting, where the majorityof decompensated patients are managed RTX001 has the potential to be the first treatment that demonstrates a clear and durable improvement in transplant free survival for ESLD patients